ASC36

unknown (auto-discovered: incretin-obesity)

Also known as: ASC36 Injection A, ASC36 Injection B, ASC36 tablets

Not graded

Classification

ResearchCompound

Regulatory Status

investigational; registered trials: NCT07893093, NCT07893106 (PHASE1)

Unofficial source

Sources

Review

pending review

Overview

Unknown — ASC36 was found by open discovery on 2026-10-26 and has not been researched yet.

Known

n/a

Unknown

Mechanism, dosing, safety, interactions and efficacy are unknown until research runs on this auto-discovered draft.

Study details: trial conditions, not guidance

These are the conditions researchers used in a controlled trial with medical supervision. They aren't instructions.

Doses as found in each source, with its grade. What was found, not a direction.

Studies, trials and professional sources

n/a

Reddit, Facebook, Instagram, forums and blogs

n/a

Not gradedASC36 is being studied in a registered trial: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Formulations of ASC36 Injection in Participants With Obesity or Overweight (NCT07893093; PHASE1; RECRUITING; sponsor Ascletis Pharma (China) Co., Limited; intervention "ASC36 Injection A, for subcutaneous use" (DRUG)).
Not gradedASC36 is being studied in a registered trial: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC36 Tablets for Oral Use in Adult Participants With Obesity or Overweight (NCT07893106; PHASE1; RECRUITING; sponsor Ascletis Pharma (China) Co., Limited; intervention "ASC36 tablets, for oral use" (DRUG)).

Educational reference only — not medical advice.

What people report (anecdote)

Adverse events:

None recorded in our sources.

Effects measured:

Human trials: none found.

ANECDOTE

Loading…